Fresenius Medical Care AG (NYSE:FM) announced updates to its commercial strategy in China aimed at driving long-term expansion and reinforcing market dominance through localized product offerings and focused commercialization.
China Commercial Strategy Optimization
The renal care provider has operated in China for over two decades, with the market generating approximately 6% to 7% of revenues within its Care Enablement operating segment.
Expanding treatment access and an increasing prevalence of chronic kidney conditions continue to drive local demand.
Shift In Product Focus And Leadership
The group will sharpen its focus on advanced in-center dialysis and critical care technology, specifically promoting high-volume hemodiafiltration systems like the 5008S CAREsystem alongside the multiFiltratePRO.
Meanwhile, the firm will stop producing and selling its 4008A hemodialysis platform locally while completely exiting the peritoneal dialysis sector in China, though it will honor existing obligations.
Financial Impact And Outlook
These operational adjustments will result in one-time special charges of roughly 110 million euros (around $125.48 million) in the third quarter of 2026, primarily stemming from asset impairments, product scrappage, and contract termination expenses.
Executives anticipate no material effect from these portfolio changes on future revenue projections for the Care Enablement segment in China.
FMS Price Action: Fresenius Medical Care shares were up 1.21% to $22.62 at the time of publication on Friday, according to Benzinga Pro data.
Image via Shutterstock
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
